Product Name: Tirofiban hydrochloride monohydrate
Synonym: TIROFIBAN, HYDROCHLORIDE HYDRATE;Tirofiban HCl;TirofibanHcl142373-60-2/;N-(Butylsulfonyl)-O-[4-(4-piperidynyl)butyl]-L-tyrosine, Hydrochloride Hydrate;(2S)-2-(Butylsulfonylamino)-3-[4-[4-(4-piperidyl)butoxy]phenyl]propanoic acid hydrochloride hydrate;N-(Butylsulfonyl)-O-(4-(4-piperidinyl)butyl)-L-tyrosine monohydrochloride monohydrate;Tirofiban hydrochloride monohydrate;Tirofiban hcl Monohydrate
MF: C22H39ClN2O6S
MW: 495.07
Product Category: Cardiovascular APIs;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;API
Melting Point: 135-137°C
Storage Temp.: -20°C Freezer
Solubility: DMSO: >12mg/mL at warmed to 60°C
Form: powder
Color: white to beige
Optical Activity: [α]/D -10 to -18° (c=1, MeOH)
Merck: 14,9464
Hazard Codes: Xi
Risk Statements: 36/37/38
Safety Statements: 26-37-45
WGK Germany: 3
Tirofiban Hyderochloride Monohydrate: Tirofiban is an anti-angina drug, it is successfully developed by the United States Merck company , Patent Number is EP 478363, and in 1998 it was sold in the United States, the trade name is Aggrastat,it is clinically used in treating acute coronary syndromes, including unstable angina or non-Q-wave myocardial infarction, and percutaneous transluminal coronary angioplasty (PTCA) or atherosclerotic plaque excision patients with in combination with heparin.
Drugs currently used in clinical are mainly tirofiban hydrochloride injections under the tradename Xin Weining, it is a reversible non-peptide platelet surface glycoprotein (GP) Ⅱb/Ⅲa receptor antagonist, it can competitively inhibit combination of fibrinogen and platelet (GP) Ⅱb/Ⅲa receptor . Intravenous injection is a dose-dependent inhibition of outside human platelet aggregation, prolonged bleeding time,and thrombosis caused by ADP, collagen, arachidonic acid,thromboxane analog U46619 and thrombin.
In healthy volunteers ,they are injected in routinely recommended doses, the peak plasma concentration is similar to that of steady-state plasma concentrations during the infusion ,T1/2 is 2h. Within 0.01~25 μg/ml dose range, PPB of this product is 65%, independent of concentration. Free drug accounts for 35% in plasma, Vd is 22~42 L. In healthy volunteers, CL is 213~314 ml/min, the renal clearance rate is 39%-69% of plasma clearance.
[Usage ]
(1) tirofiban hydrochloride monohydrate in combination with heparin is used in treating acute coronary syndromes, including unstable angina or non-Q-wave myocardial infarction, and percutaneous transluminal coronary angioplasty (PTCA) or atherectomy artery surgery patients.
(2) to give this product 0.4μg/(kg · min) bolus, 300 min, followed by a maintenance dose of 0.1μg/(kg · min). Unstable angina or non-Q-wave myocardial infarction patients need an infusion of 48~108 h. Row PTCA or atherectomy arterial patients need to continue infusion 12~24 h after surgery.
Precaution: 1. Adverse reactions: The most common adverse reactions are fever, or bleeding complications; other visible adverse reactions are nausea, headache, rash or urticaria, systemic reactions visible is reduction in platelet count.
2. Disable: allergy to the drug, the use of tirofiban in patients with thrombocytopenia occurring, there is active bleeding or bleeding constitution history before 30 days, history of intracranial hemorrhage, nearly a month of stroke or brain hemorrhage stroke, intracranial tumors, aneurysms, arteriovenous malformations, vital organs, surgery or severe trauma requiring surgical treatment, patients with aortic dissection, pericarditis, severe hypertension.
3. caution: recent (1 year) bleeding in patients, with coagulopathy, platelet disorder, or a history of thrombocytopenia, platelet count less than 150 × 109/L patients who have a history of cerebrovascular disease (1 year) , with recent subdural extracapsular surgery, nearly a month having a major surgery or a history of severe physical trauma, dissecting aneurysm, hemorrhagic retinal diseases, chronic hemodialysis patients.
Uses: Acute coronary syndrome (angina pectoris, myocardial infarction, surgery hydrant).
Tirofiban hydrochloride monohydrate is a potent non-peptide, glycoprotein IIb/IIIa inhibitor. It can prevent platelet aggregation and thrombosis.
Chemical Property: White Solid
Uses: A specific nonpeptide platelet fibrinogen receptor (GPIIb/IIIa) antagonist. An antithrombotic used in the treatment of unstable angina
Uses: Tirofiban is a specific nonpeptide platelet fibrinogen receptor (GPIIb/IIIa) antagonist. Tirofiban is an antithrombotic used in the treatment of unstable angina.
關鍵字: 原料藥與中間體;
一般項目:第二類醫(yī)療器械銷售;針紡織品及原料批發(fā);服裝復試批發(fā);日用百貨銷售;家用電器銷售;第一類醫(yī)療器械銷售;化工產(chǎn)品銷售(不含許可類化工產(chǎn)品);五金產(chǎn)品批發(fā);計算機軟硬件及輔助設備批發(fā);化妝品批發(fā);消毒劑銷售(不含危險化學品);專用化學產(chǎn)品銷售(不含危驗化學品);個人衛(wèi)生用品銷售;金屬材料售;醫(yī)用口罩批發(fā);日用口罩(非醫(yī)用)銷售;醫(yī)護人員防護用品批發(fā);衛(wèi)生用品和一次性使用醫(yī)療用品銷售;勞動保護用品確售;合成材料銷售;飼料添加劑銷售;藥物檢測儀器銷售;制藥專用設備銷售;財務咨詢;信息咨詢服務(不含許可類信息咨詢服務);技術服務、技術開發(fā)、技術咨詢、技術交流、技術轉讓、技術推廣;染料銷售;衛(wèi)生用品銷售;建筑裝飾材料銷售;電子辦公設備銷售;針紡識品銷售;貿(mào)易經(jīng)紀;銷售代理;國內貿(mào)易代理(除依法須經(jīng)批準的項目外,憑營業(yè)執(zhí)照依法自主開展經(jīng)營活動)。許可項目∶食品經(jīng)營(銷售預包裝食品);貨物進出口;藥品進出口;進出口代理;技術進出口(依法須經(jīng)批準的項目,經(jīng)相關部門批批準方可開展經(jīng)營活動,具體經(jīng)營項目以審批結果為準)。